Create an image of Pathology of parkinson disease in 4:5 ratio size also it's clinical features
Medical educational poster about Parkinson's Disease in portrait 4:5 ratio. Split into two main sections: TOP SECTION - "PATHOLOGY OF PARKINSON'S DISEASE": - Illustration of the substantia nigra showing dopaminergic neuron loss (dark pigmented neurons depleted vs normal side comparison) - Lewy body diagram: eosinophilic intracytoplasmic inclusion with dense core and pale halo, labeled with alpha-synuclein aggregates - Basal ganglia circuit diagram showing: Striatum, Substantia Nigra pars compacta (SNc), Globus Pallidus, Subthalamic Nucleus - with arrows showing disrupted dopaminergic pathway (dopamine deficiency) - Cross-section of midbrain showing depigmented substantia nigra (pale vs normal dark) - Labels: "Loss of dopaminergic neurons in SNc", "Lewy Bodies (α-synuclein)", "Reduced dopamine → increased inhibitory output" BOTTOM SECTION - "CLINICAL FEATURES": Cardinal Motor Features box: • Resting Tremor (3-5 Hz, pill-rolling) • Rigidity (cogwheel/lead pipe) • Bradykinesia (slowness of movement) • Postural Instability Non-Motor Features box: • Autonomic: orthostatic hypotension, constipation, seborrhea • Neuropsychiatric: dementia, depression, hallucinations • Sleep: REM sleep behavior disorder • Olfactory: hyposmia/anosmia Clinical Signs box: • Shuffling gait, festination • Micrographia • Hypomimia (masked face) • Hypophonia • Stooped posture Color scheme: deep blue and teal background, white text, gold/amber accents for key labels, clean medical illustration style, anatomical accuracy
- Depigmented substantia nigra (SNc) due to dopaminergic neuron loss
- Lewy body structure with alpha-synuclein aggregates
- Disrupted basal ganglia circuit showing dopamine deficiency pathway
- Cardinal motor signs: Resting tremor (pill-rolling, 3-5 Hz), rigidity (cogwheel/lead pipe), bradykinesia, postural instability
- Non-motor signs: Autonomic dysfunction, neuropsychiatric symptoms (dementia, depression), REM sleep behavior disorder, hyposmia
- Clinical signs: Shuffling gait, micrographia, hypomimia (masked face), hypophonia, stooped posture
Treatment of parkinson disease
"Parkinson disease" AND treatment
Treatment of Parkinson's Disease
General Principles
1. Levodopa (Gold Standard)
- Carbidopa/benserazide are peripheral dopa decarboxylase inhibitors that prevent peripheral conversion of levodopa, reducing nausea and allowing more levodopa to cross the blood-brain barrier.
- Typical starting dose: carbidopa/levodopa 25/100 mg 2-3 times daily, titrated upward.
- Even after 20+ years, most classic motor features continue to respond.
| Complication | Description | Management |
|---|---|---|
| Wearing-off / End-of-dose | Symptoms return before next dose | Increase dose frequency; use CR formulation; add COMT or MAO-B inhibitor |
| Dyskinesias (peak-dose) | Involuntary choreiform/dystonic movements at peak levels | Reduce individual doses; add amantadine |
| "On-Off" fluctuations | Unpredictable switching between good and poor control | Dopamine agonist add-on; apomorphine rescue |
- Controlled-release (Sinemet CR) - less fluctuation
- Inhaled levodopa (Inbrija) - onset within 10 minutes for sudden "off" episodes
- Intrajejunal infusion (Duopa/Duodopa) - continuous duodenal delivery for severe fluctuations; significantly improves "off" time without increasing dyskinesias
- Continuous subcutaneous levodopa prodrugs - a promising emerging option
2. Dopamine Agonists
| Drug | Type | Route |
|---|---|---|
| Pramipexole (Mirapex) | Non-ergot D2/D3 agonist | Oral |
| Ropinirole (Requip) | Non-ergot D2/D3 agonist | Oral |
| Rotigotine (Neupro) | Non-ergot | Transdermal patch |
| Apomorphine | D1/D2 agonist | SC injection / sublingual film |
- Excessive somnolence, "sleep attacks"
- Leg edema
- Hallucinations (especially in elderly/cognitively impaired)
- Impulse control disorders (pathological gambling, hypersexuality, binge eating, compulsive shopping) - occurs in 1 in 6 patients; family monitoring is strongly recommended.
3. MAO-B Inhibitors
| Drug | Notes |
|---|---|
| Selegiline (deprenyl) | Also mild stimulant effect; metabolized to amphetamine |
| Rasagiline (Azilect) | Cleaner profile; may have mild neuroprotective properties (unproven in humans) |
| Safinamide (Xadago) | Also has glutamate/sodium channel modulation |
- Used as monotherapy in early disease or adjunct to levodopa for wearing-off.
- Extend "on" time by ~1 hour/day when used with levodopa.
4. COMT Inhibitors
| Drug | Notes |
|---|---|
| Entacapone (Comtan) | Peripheral only; given with each levodopa dose |
| Opicapone (Ongentys) | Once-daily dosing |
| Tolcapone (Tasmar) | Central + peripheral; hepatotoxic - requires LFT monitoring |
| Levodopa/carbidopa/entacapone (Stalevo) | Fixed-dose combination |
- Primarily used to manage wearing-off fluctuations.
- Increase "on" time by ~1-2 hours/day.
- Side effects: orange urine discoloration, diarrhea, worsened dyskinesias.
5. Amantadine
- An NMDA receptor antagonist with mild dopaminergic properties.
- Used to treat levodopa-induced dyskinesias without worsening parkinsonism.
- Also useful in early mild PD as monotherapy.
- Extended-release amantadine (Gocovri) - specifically FDA-approved for dyskinesia.
- Side effects: livedo reticularis, ankle edema, confusion (especially in elderly).
6. Istradefylline (Nourianz)
- Adenosine A2A receptor antagonist (non-dopaminergic mechanism).
- Approved as adjunct to levodopa to reduce "off" time.
- Mechanism: modulates indirect basal ganglia pathway independently of dopamine.
7. Anticholinergics
| Drug | Use |
|---|---|
| Trihexyphenidyl | Tremor-predominant young patients |
| Benztropine | Tremor; also used in drug-induced parkinsonism |
- Less used now due to side effects: dry mouth, urinary retention, constipation, confusion, memory impairment.
- Avoid in elderly and cognitively impaired patients.
- Most useful for tremor refractory to dopaminergic therapy.
8. Surgical Treatment
Deep Brain Stimulation (DBS)
- Most effective surgical treatment for PD.
- Targets: Subthalamic nucleus (STN) or globus pallidus interna (GPi).
- Indications: Motor fluctuations/dyskinesias refractory to medical therapy; tremor-dominant PD unresponsive to medication.
- Improves motor function by ~50% in "off" state; reduces dyskinesias.
- Contraindications: Dementia, significant psychiatric disease, poor levodopa response (except tremor).
Focused Ultrasound (MRI-guided)
- Unilateral thalamotomy for tremor-dominant PD.
- Non-invasive; FDA-approved.
9. Non-Motor Symptom Management
| Symptom | Treatment |
|---|---|
| Depression | SSRIs (sertraline, citalopram); SNRIs; TCAs with caution |
| Psychosis/Hallucinations | Clozapine (most evidence), quetiapine; pimavanserin (Nuplazid - 5-HT2A antagonist, FDA-approved) |
| Dementia | Rivastigmine (only AChEI FDA-approved for PD dementia) |
| Orthostatic hypotension | Fludrocortisone, midodrine, droxidopa |
| Constipation | Fiber, osmotic laxatives, macrogol |
| REM sleep behavior disorder | Melatonin, low-dose clonazepam |
| Sialorrhea (drooling) | Botulinum toxin injections to salivary glands |
| Dysphagia | Speech therapy, modified barium swallow assessment |
| Urinary urgency | Solifenacin, trospium (avoid oxybutynin - cognitive effects) |
10. Neuroprotective/Emerging Therapies
- GLP-1 receptor agonists (e.g., liraglutide, semaglutide) - under investigation for neuroprotection.
- Alpha-synuclein-targeted therapies (monoclonal antibodies, antisense oligonucleotides) - in clinical trials.
- Gene therapy - ongoing trials for AADC gene delivery to striatum.
- Exercise has growing evidence for slowing motor decline and improving neuroplasticity.
Treatment Summary by Stage
| Disease Stage | First-line Approach |
|---|---|
| Early, young (<65), cognitively intact | Dopamine agonist monotherapy |
| Early, older (>65) or cognitively impaired | Levodopa/carbidopa |
| Mild symptoms, any age | MAO-B inhibitor (rasagiline/selegiline) |
| Motor fluctuations / wearing-off | Add COMT inhibitor or MAO-B inhibitor; increase levodopa frequency |
| Peak-dose dyskinesias | Reduce levodopa dose; add amantadine |
| Refractory fluctuations/dyskinesias | Deep Brain Stimulation |
| Tremor-dominant, refractory | DBS-STN or focused ultrasound thalamotomy |
Create an Image of parkinson disease treatment
Create an Image of parkinson disease treatment in 4: 5ratio size
Medical educational poster "TREATMENT OF PARKINSON'S DISEASE" in portrait 4:5 ratio. Dark navy blue background with clean, professional medical illustration style. Organized into clearly labeled sections with icons and color-coded boxes. TITLE at top: "TREATMENT OF PARKINSON'S DISEASE" in bold gold/amber text with a brain icon. SECTION 1 - "PHARMACOLOGICAL TREATMENT" (light teal header): Box 1 - LEVODOPA (GOLD STANDARD) in yellow: • Levodopa + Carbidopa / Benserazide • Most effective motor symptom control • Complications: Wearing-off, Peak-dose Dyskinesias, On-Off fluctuations • Formulations: Immediate release, Controlled release, Inhaled (Inbrija), Intrajejunal infusion (Duopa) Box 2 - DOPAMINE AGONISTS in blue: • Pramipexole, Ropinirole (oral) • Rotigotine (transdermal patch) • Apomorphine (SC injection / sublingual film) • Preferred in young patients <65 yrs • Risk: Impulse control disorders, hallucinations Box 3 - MAO-B INHIBITORS in green: • Selegiline, Rasagiline, Safinamide • Extend dopamine action • Early monotherapy or adjunct to levodopa Box 4 - COMT INHIBITORS in orange: • Entacapone, Opicapone, Tolcapone • Reduce wearing-off fluctuations • Stalevo = Levodopa + Carbidopa + Entacapone Box 5 - OTHER DRUGS in purple: • Amantadine → treats dyskinesias (NMDA antagonist) • Istradefylline → A2A adenosine antagonist • Anticholinergics (Trihexyphenidyl) → tremor only SECTION 2 - "SURGICAL TREATMENT" (red/coral header): • Deep Brain Stimulation (DBS): STN or GPi targets → Motor fluctuations & dyskinesias • Focused Ultrasound Thalamotomy → Tremor-dominant PD SECTION 3 - "NON-MOTOR MANAGEMENT" (pink header): • Depression → SSRIs / SNRIs • Psychosis → Pimavanserin, Clozapine • Dementia → Rivastigmine • Orthostatic hypotension → Midodrine, Droxidopa • Sialorrhea → Botulinum toxin SECTION 4 - "REHABILITATION" (light green): • Physiotherapy • Speech therapy • Occupational therapy • Exercise programs Small human silhouette showing stooped Parkinson's posture in bottom corner. Clean icons for each section. White text throughout. Compact, readable layout.
- Levodopa (Gold Standard) - with formulation options and complication management
- Dopamine Agonists - pramipexole, ropinirole, rotigotine, apomorphine
- MAO-B Inhibitors - selegiline, rasagiline, safinamide
- COMT Inhibitors - entacapone, opicapone, tolcapone
- Other Drugs - amantadine (dyskinesias), istradefylline, anticholinergics (tremor)
- Surgical - Deep Brain Stimulation (STN/GPi) and Focused Ultrasound
- Non-motor management - psychosis, depression, dementia, autonomic symptoms
- Rehabilitation - physiotherapy, speech therapy, exercise
Change background colour of image
Medical educational poster "TREATMENT OF PARKINSON'S DISEASE" in portrait 4:5 ratio. Deep rich purple background with clean, professional medical illustration style. Organized into clearly labeled sections with icons and color-coded boxes. TITLE at top: "TREATMENT OF PARKINSON'S DISEASE" in bold gold/amber text with a brain icon. SECTION 1 - "PHARMACOLOGICAL TREATMENT" (bright teal header): Box 1 - LEVODOPA (GOLD STANDARD) in warm yellow box: • Levodopa + Carbidopa / Benserazide • Most effective motor symptom control • Complications: Wearing-off, Peak-dose Dyskinesias, On-Off fluctuations • Formulations: Immediate release, Controlled release, Inhaled (Inbrija), Intrajejunal infusion (Duopa) Box 2 - DOPAMINE AGONISTS in sky blue box: • Pramipexole, Ropinirole (oral) • Rotigotine (transdermal patch) • Apomorphine (SC injection / sublingual film) • Preferred in young patients less than 65 yrs • Risk: Impulse control disorders, hallucinations Box 3 - MAO-B INHIBITORS in bright green box: • Selegiline, Rasagiline, Safinamide • Extend dopamine action • Early monotherapy or adjunct to levodopa Box 4 - COMT INHIBITORS in bright orange box: • Entacapone, Opicapone, Tolcapone • Reduce wearing-off fluctuations • Stalevo = Levodopa + Carbidopa + Entacapone Box 5 - OTHER DRUGS in magenta box: • Amantadine - treats dyskinesias (NMDA antagonist) • Istradefylline - A2A adenosine antagonist • Anticholinergics (Trihexyphenidyl) - tremor only SECTION 2 - "SURGICAL TREATMENT" (coral red header): • Deep Brain Stimulation (DBS): STN or GPi targets - Motor fluctuations and dyskinesias • Focused Ultrasound Thalamotomy - Tremor-dominant PD SECTION 3 - "NON-MOTOR MANAGEMENT" (pink header): • Depression - SSRIs / SNRIs • Psychosis - Pimavanserin, Clozapine • Dementia - Rivastigmine • Orthostatic hypotension - Midodrine, Droxidopa • Sialorrhea - Botulinum toxin SECTION 4 - "REHABILITATION" (lime green): • Physiotherapy • Speech therapy • Occupational therapy • Exercise programs Small human silhouette showing stooped Parkinson's posture in bottom corner. Clean icons for each section. White text throughout. Deep purple main background. Compact, readable layout.
In white colour
Medical educational poster "TREATMENT OF PARKINSON'S DISEASE" in portrait 4:5 ratio. Clean WHITE background with professional medical illustration style. Organized into clearly labeled sections with icons and color-coded boxes. TITLE at top: "TREATMENT OF PARKINSON'S DISEASE" in bold dark navy blue text with a brain icon. Thin colored divider line below title. SECTION 1 - "PHARMACOLOGICAL TREATMENT" (dark teal header bar): Box 1 - LEVODOPA (GOLD STANDARD) with yellow/amber border: • Levodopa + Carbidopa / Benserazide • Most effective motor symptom control • Complications: Wearing-off, Peak-dose Dyskinesias, On-Off fluctuations • Formulations: Immediate release, Controlled release, Inhaled (Inbrija), Intrajejunal infusion (Duopa) Box 2 - DOPAMINE AGONISTS with blue border: • Pramipexole, Ropinirole (oral) • Rotigotine (transdermal patch) • Apomorphine (SC injection / sublingual film) • Preferred in young patients less than 65 yrs • Risk: Impulse control disorders, hallucinations Box 3 - MAO-B INHIBITORS with green border: • Selegiline, Rasagiline, Safinamide • Extend dopamine action • Early monotherapy or adjunct to levodopa Box 4 - COMT INHIBITORS with orange border: • Entacapone, Opicapone, Tolcapone • Reduce wearing-off fluctuations • Stalevo = Levodopa + Carbidopa + Entacapone Box 5 - OTHER DRUGS with purple border: • Amantadine - treats dyskinesias (NMDA antagonist) • Istradefylline - A2A adenosine antagonist • Anticholinergics (Trihexyphenidyl) - tremor only SECTION 2 - "SURGICAL TREATMENT" (red header bar): • Deep Brain Stimulation (DBS): STN or GPi targets - Motor fluctuations and dyskinesias • Focused Ultrasound Thalamotomy - Tremor-dominant PD SECTION 3 - "NON-MOTOR MANAGEMENT" (pink header bar): • Depression - SSRIs / SNRIs • Psychosis - Pimavanserin, Clozapine • Dementia - Rivastigmine • Orthostatic hypotension - Midodrine, Droxidopa • Sialorrhea - Botulinum toxin SECTION 4 - "REHABILITATION" (green header bar): • Physiotherapy • Speech therapy • Occupational therapy • Exercise programs All text in dark charcoal/black for readability. White background throughout. Colored borders and headers for each section. Clean, minimal, clinical style. Small brain and human silhouette icons. Compact and well-organized layout.
- Yellow - Levodopa (Gold Standard)
- Blue - Dopamine Agonists
- Green - MAO-B Inhibitors
- Orange - COMT Inhibitors
- Purple - Other Drugs
- Red - Surgical Treatment
- Pink - Non-Motor Management
- Green - Rehabilitation
Give white colour in background
Medical educational poster "PARKINSON'S DISEASE" in portrait 4:5 ratio. PURE WHITE background throughout. Same layout and content as the original but with white background and dark text. TITLE at very top: "PARKINSON'S DISEASE" in large bold dark navy blue text, with thin gold decorative lines on both sides. TOP SECTION - "PATHOLOGY OF PARKINSON'S DISEASE" in dark teal header bar with white text: LEFT SIDE: - "SUBSTANTIA NIGRA NEURON LOSS" label in dark gold/amber - Two midbrain cross-section illustrations side by side: LEFT labeled "NORMAL" (dark pigmented substantia nigra), RIGHT labeled "PARKINSON'S DISEASE" (pale depigmented substantia nigra) - Arrow between them pointing right - Label: "Loss of dopaminergic neurons in SNc" - Below: another midbrain cross-section comparison labeled "MIDBRAIN CROSS-SECTION" - NORMAL vs PARKINSON'S DISEASE labels - Label: "Depigmented substantia nigra" RIGHT SIDE: - "LEWY BODY" label in dark gold/amber - Detailed neuron illustration with large pink/red Lewy body inclusion inside - Labels: "Lewy Bodies (α-synuclein)" and "α-synuclein aggregates" CENTER-RIGHT: - "BASAL GANGLIA CIRCUIT" label - Circuit diagram showing: STRIATUM (caudate, putamen) at top, GLOBUS PALLIDUS (external and internal segments), SUBTHALAMIC NUCLEUS at bottom, SUBSTANTIA NIGRA pars compacta (SNc) - "DOPAMINERGIC PATHWAY" label with yellow arrow - Red X symbol labeled "DOPAMINE DEFICIENCY" - Label: "Reduced dopamine → increased inhibitory output" - Arrows showing circuit connections in teal/blue BOTTOM SECTION - "CLINICAL FEATURES" in dark teal header bar with white text: Three columns with light colored box borders on white background: Column 1 - "CARDINAL MOTOR FEATURES" (gold/amber border box): - Hand tremor icon • Resting Tremor (3-5 Hz, pill-rolling) - Arm icon • Rigidity (cogwheel/lead pipe) - Running figure icon • Bradykinesia (slowness of movement) - Balance icon • Postural Instability Column 2 - "NON-MOTOR FEATURES" (teal border box): - Blood pressure icon • Autonomic: orthostatic hypotension, constipation, seborrhea - Brain icon • Neuropsychiatric: dementia, depression, hallucinations - Sleep icon • Sleep: REM sleep behavior disorder - Nose icon • Olfactory: hyposmia/anosmia Column 3 - "CLINICAL SIGNS" (gold border box): - Walking icon • Shuffling gait, festination - Writing icon • Micrographia - Face icon • Hypomimia (masked face) - Speech icon • Hypophonia - Posture icon • Stooped posture All text in dark charcoal or navy blue. White background everywhere. Colored anatomical illustrations with labels. Clean medical diagram style. Gold accent lines and borders.
- Pathology section - Substantia nigra neuron loss, midbrain cross-sections, Lewy body illustration, and Basal Ganglia circuit diagram
- Clinical Features section - Cardinal motor features, non-motor features, and clinical signs